Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
10103721 | Journal of the American College of Surgeons | 2005 | 11 Pages |
Abstract
These results provide additional data to plan clinical trials to answer the question of who can safely avoid CLND after a positive SLN. Patients with minimal tumor burden in the SLN might be the most likely group, although defining “minimal tumor burden” must be standardized. Serial sectioning and immunohistochemistry on the NSLN in any “low-risk” group must be performed in a clinical trial to confirm that residual disease is unlikely before avoiding CLND can be recommended.
Keywords
Related Topics
Health Sciences
Medicine and Dentistry
Surgery
Authors
Michael S. (FACS), Kent MPH, MS, Vernon K. (FACS), Lori MD, Jennifer L. MD, Vincent M. (FACS), Alfred E. (FACS), Riley S. (FACS), Carol R. (FACS), Timothy M. MD,